121 related articles for article (PubMed ID: 15044053)
21. Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis.
Tavakkolizadeh A; Shen R; Abraham P; Kormi N; Seifert P; Edelman ER; Jacobs DO; Zinner MJ; Ashley SW; Whang EE
J Surg Res; 2000 Jun; 91(1):77-82. PubMed ID: 10816354
[TBL] [Abstract][Full Text] [Related]
22. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.
Martin GR; Wallace LE; Hartmann B; Holst JJ; Demchyshyn L; Toney K; Sigalet DL
Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G431-8. PubMed ID: 15388486
[TBL] [Abstract][Full Text] [Related]
23. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
[TBL] [Abstract][Full Text] [Related]
24. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.
Anini Y; Izzo A; Oudit GY; Backx PH; Brubaker PL
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1599-606. PubMed ID: 17284578
[TBL] [Abstract][Full Text] [Related]
25. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
26. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
27. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Deacon CF; Holst JJ
Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
[TBL] [Abstract][Full Text] [Related]
30. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
31. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Lenhard JM; Croom DK; Minnick DT
Biochem Biophys Res Commun; 2004 Nov; 324(1):92-7. PubMed ID: 15464987
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
Bulut K; Meier JJ; Ansorge N; Felderbauer P; Schmitz F; Hoffmann P; Schmidt WE; Gallwitz B
Regul Pept; 2004 Sep; 121(1-3):137-43. PubMed ID: 15256284
[TBL] [Abstract][Full Text] [Related]
33. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
Thulesen J; Hartmann B; Hare KJ; Kissow H; Ørskov C; Holst JJ; Poulsen SS
Gut; 2004 Aug; 53(8):1145-50. PubMed ID: 15247183
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
36. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
37. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Yoshikawa S; Asano O; Tanaka I
Biochem Biophys Res Commun; 2001 Jun; 284(2):501-6. PubMed ID: 11394909
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
39. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, secretion and biological actions of the glucagon-like peptides.
Lovshin J; Drucker DJ
Pediatr Diabetes; 2000 Mar; 1(1):49-57. PubMed ID: 15016242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
